OBJECTIVES: The present study was planned to investigate the relationship between the plasma lipid profile and disease activity in patients with a first clinical episode suggestive of multiple sclerosis (MS). MATERIAL AND METHODS: Eighteen consecutive out-patients underwent a monthly brain magnetic resonance imaging (MRI), blood sample and neurological assessment over 6 months. Blood samples were used to evaluate total cholesterol and triglyceride levels as well as their lipoprotein fractions. Plasma total apolipoprotein E concentration was also determined. RESULTS: We found a significant correlation between the mean number of enhancing lesions and the mean plasma level of both total and low density lipoprotein cholesterol. The total plasma cholesterol level increased on average by 4.4 mg/dl for each enhancing lesion. CONCLUSION: Our preliminary data suggest a potential role of plasma cholesterol level as a biological marker of disease activity after a first demyelinating event. Further studies need, however, to be designed to determine whether the plasma cholesterol level is of practical use in monitoring the disease course.
OBJECTIVES: The present study was planned to investigate the relationship between the plasma lipid profile and disease activity in patients with a first clinical episode suggestive of multiple sclerosis (MS). MATERIAL AND METHODS: Eighteen consecutive out-patients underwent a monthly brain magnetic resonance imaging (MRI), blood sample and neurological assessment over 6 months. Blood samples were used to evaluate total cholesterol and triglyceride levels as well as their lipoprotein fractions. Plasma total apolipoprotein E concentration was also determined. RESULTS: We found a significant correlation between the mean number of enhancing lesions and the mean plasma level of both total and low density lipoprotein cholesterol. The total plasma cholesterol level increased on average by 4.4 mg/dl for each enhancing lesion. CONCLUSION: Our preliminary data suggest a potential role of plasma cholesterol level as a biological marker of disease activity after a first demyelinating event. Further studies need, however, to be designed to determine whether the plasma cholesterol level is of practical use in monitoring the disease course.
Authors: Kelly Fellows; Tomas Uher; Richard W Browne; Bianca Weinstock-Guttman; Dana Horakova; Helena Posova; Manuela Vaneckova; Zdenek Seidl; Jan Krasensky; Michaela Tyblova; Eva Havrdova; Robert Zivadinov; Murali Ramanathan Journal: J Lipid Res Date: 2015-08-04 Impact factor: 5.922
Authors: Yulin Ge; Meng Law; Glyn Johnson; Joseph Herbert; James S Babb; Lois J Mannon; Robert I Grossman Journal: AJNR Am J Neuroradiol Date: 2005 Jun-Jul Impact factor: 3.825
Authors: Giuseppe Salemi; Maria Concetta Gueli; Francesco Vitale; Floriana Battaglieri; Egidio Guglielmini; Paolo Ragonese; Angela Trentacosti; Maria Fatima Massenti; Giovanni Savettieri; Antonino Bono Journal: Lipids Health Dis Date: 2010-02-18 Impact factor: 3.876